← boardnext 2027-12-31
KNSA
Kiniksa Pharmaceuticals International, plcdistress 0/10 · well-funded / low risk$62.270%today-7% from 52w high
Lead: Recurrent Pericarditis
Revenue
$214M
Liquidity
$468M
Runway
—
Shares 1y
—
Price & events
+46.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.3%
1D
+1.9%
1W
+4.7%
1M
+44.6%
3M
+47.6%
6M
+129.6%
1Y
+136.9%
2Y
+329.4%
5Y
+264.8%
All
Overview
- Volume
- 25.20K
- 52 Week Range
- $26.33 – $67.29
- Float Shares
- 42.20M
- Short %
- 10.93%
- % Held by Insiders
- 3.58%
- % Held by Institutions
- 102.65%
- RVOL
- 0.03x
- Beta
- 0.07
Pipeline stages · 2 programs
KPL-387
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Abiprubart
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-12-31 Estimated 50% readout ~2028-02-14 | Phase 2 | KPL-387 | Recurrent Pericarditis, Heart Diseases, Pericarditis | — | recruiting |
| 2027-12-31 Estimated 50% readout ~2028-03-15 | Phase 2/3 | KPL-387 | Pericarditis, Pericarditis Acute, Recurrent Pericarditis | — | recruiting |
| 2025-03-06 | Phase 2 | Abiprubart | Sjögrens Disease | 3 | terminated |
Catalyst news & presentations · 3
- second half of 2026Guided 55%readoutPhase 2KPL-387 · Phase 2 dose-focusing data expectedSEC 8-K
- 2026-07-28Estimated 45%earningsEarningsEarnings releaseyahoo
- mid-2025trial initiationsecondaryPhase 2/3KPL-387 · Initiate Phase 2/3 clinical trialSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $68 (+9% upside) · 8 analysts
- 2026-07-13Wells FargoOverweight
- 2026-06-29WedbushOutperform
- 2026-04-29Canaccord GenuityBuy
- 2026-04-29WedbushOutperform
- 2026-04-29CitigroupBuy
- 2026-04-29Wells FargoOverweight
Competitors — Recurrent Pericarditis
- CRDLCardiol Therapeutics Inc.$128M · D4
Recent news
- 2026-07-22Recent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's Why - Yahoo! Finance Canada
- 2026-07-21Kiniksa Pharmaceuticals (NASDAQ:KNSA) Qualifies as an Affordable Growth Stock With Strong Revenue and Earnings Momentum - ChartMill
- 2026-07-17Kiniksa Pharmaceuticals International PLC (KNSA) Shares Surge 4. - GuruFocus
- 2026-07-16Price to sales forward of Kiniksa Pharmaceuticals International, plc – NASDAQ:KNSA - TradingView
- 2026-07-16Price to book forward of Kiniksa Pharmaceuticals International, plc – NASDAQ:KNSA - TradingView
- 2026-07-15Kiniksa Pharmaceuticals: Leader In Pericarditis Merits Hold Rating After Recent Gains - Seeking Alpha
- 2026-07-13KNSA Maintained by Wells Fargo -- Price Target Raised to $74.00 - GuruFocus
- 2026-07-12Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.